Last reviewed · How we verify
carboplatin paclitaxel bevacizumab
carboplatin paclitaxel bevacizumab is a Chemotherapy combination with anti-angiogenic monoclonal antibody Small molecule drug developed by Gruppo Oncologico Italia Meridionale. It is currently in Phase 3 development for Advanced or metastatic non-small cell lung cancer, Ovarian cancer, Breast cancer. Also known as: Taxol, Avastin.
This combination uses carboplatin and paclitaxel as chemotherapy agents to damage cancer cell DNA and disrupt microtubules, while bevacizumab blocks angiogenesis by inhibiting vascular endothelial growth factor (VEGF).
This combination uses carboplatin and paclitaxel as chemotherapy agents to damage cancer cell DNA and disrupt microtubules, while bevacizumab blocks angiogenesis by inhibiting vascular endothelial growth factor (VEGF). Used for Advanced or metastatic non-small cell lung cancer, Ovarian cancer, Breast cancer.
At a glance
| Generic name | carboplatin paclitaxel bevacizumab |
|---|---|
| Also known as | Taxol, Avastin |
| Sponsor | Gruppo Oncologico Italia Meridionale |
| Drug class | Chemotherapy combination with anti-angiogenic monoclonal antibody |
| Target | DNA (carboplatin), microtubules (paclitaxel), VEGF (bevacizumab) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Carboplatin is a platinum-based alkylating agent that cross-links DNA and prevents replication. Paclitaxel is a taxane that stabilizes microtubules and prevents cell division. Bevacizumab is a monoclonal antibody against VEGF that inhibits tumor blood vessel formation, reducing nutrient supply to cancer cells. Together, these agents provide complementary cytotoxic and anti-angiogenic effects.
Approved indications
- Advanced or metastatic non-small cell lung cancer
- Ovarian cancer
- Breast cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Neuropathy
- Nausea and vomiting
- Hypertension
- Proteinuria
- Bleeding events
Key clinical trials
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
- A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors (PHASE1, PHASE2)
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (PHASE1, PHASE2)
- Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) (PHASE3)
- A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer (PHASE3)
- Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- carboplatin paclitaxel bevacizumab CI brief — competitive landscape report
- carboplatin paclitaxel bevacizumab updates RSS · CI watch RSS
- Gruppo Oncologico Italia Meridionale portfolio CI
Frequently asked questions about carboplatin paclitaxel bevacizumab
What is carboplatin paclitaxel bevacizumab?
How does carboplatin paclitaxel bevacizumab work?
What is carboplatin paclitaxel bevacizumab used for?
Who makes carboplatin paclitaxel bevacizumab?
Is carboplatin paclitaxel bevacizumab also known as anything else?
What drug class is carboplatin paclitaxel bevacizumab in?
What development phase is carboplatin paclitaxel bevacizumab in?
What are the side effects of carboplatin paclitaxel bevacizumab?
What does carboplatin paclitaxel bevacizumab target?
Related
- Drug class: All Chemotherapy combination with anti-angiogenic monoclonal antibody drugs
- Target: All drugs targeting DNA (carboplatin), microtubules (paclitaxel), VEGF (bevacizumab)
- Manufacturer: Gruppo Oncologico Italia Meridionale — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Advanced or metastatic non-small cell lung cancer
- Indication: Drugs for Ovarian cancer
- Indication: Drugs for Breast cancer
- Also known as: Taxol, Avastin
- Compare: carboplatin paclitaxel bevacizumab vs similar drugs
- Pricing: carboplatin paclitaxel bevacizumab cost, discount & access